Therapeutic strategies for COVID-19: progress and lessons learned

G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

SARS-CoV-2 pathogenesis

MM Lamers, BL Haagmans - Nature reviews microbiology, 2022 - nature.com
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
caused a devastating pandemic. Although most people infected with SARS-CoV-2 develop …

An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment

S Drożdżal, J Rosik, K Lechowicz, F Machaj… - Drug Resistance …, 2021 - Elsevier
The COVID-19 pandemic is one of the greatest threats to human health in the 21st century
with more than 257 million cases and over 5.17 million deaths reported worldwide (as of …

COVID-19 therapeutics: Challenges and directions for the future

PC Robinson, DFL Liew, HL Tanner… - Proceedings of the …, 2022 - National Acad Sciences
The emergence of SARS-CoV-2 triggering the COVID-19 pandemic ranks as arguably the
greatest medical emergency of the last century. COVID-19 has highlighted health disparities …

The development of COVID-19 treatment

Y Yuan, B Jiao, L Qu, D Yang, R Liu - Frontiers in immunology, 2023 - frontiersin.org
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused
a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest …

COVID-19 and metabolic disease: mechanisms and clinical management

C Steenblock, PEH Schwarz, B Ludwig… - The lancet Diabetes & …, 2021 - thelancet.com
Up to 50% of the people who have died from COVID-19 had metabolic and vascular
disorders. Notably, there are many direct links between COVID-19 and the metabolic and …

Infectious Diseases Society of America Guidelines on the treatment and management of patients with coronavirus disease 2019 (COVID-19)

A Bhimraj, RL Morgan, AH Shumaker… - Clinical Infectious …, 2020 - academic.oup.com
Background There are many pharmacologic therapies that are being used or considered for
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …

Host genetic factors determining COVID-19 susceptibility and severity

TP Velavan, SR Pallerla, J Rüter, Y Augustin… - …, 2021 - thelancet.com
The COVID-19 pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus-2
(SARS-CoV-2) poses an unprecedented challenge to humanity. SARS-CoV-2 infections …

Potential therapeutic options for COVID-19: an update on current evidence

Z Niknam, A Jafari, A Golchin, F Danesh Pouya… - European journal of …, 2022 - Springer
Abstract SARS-CoV-2, a novel coronavirus, is the agent responsible for the COVID-19
pandemic and is a major public health concern nowadays. The rapid and global spread of …

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive …

LM Yu, M Bafadhel, J Dorward, G Hayward, BR Saville… - The Lancet, 2021 - thelancet.com
Background A previous efficacy trial found benefit from inhaled budesonide for COVID-19 in
patients not admitted to hospital, but effectiveness in high-risk individuals is unknown. We …